Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., a full-service, 480-lawyer AmLaw 100 firm with offices throughout the U.S. and in the U.K., announced it advised CVS...
CVS Corporation and Caremark Rx, Inc. today announced that they have formally closed their transformative merger of equals, creating the nation?s premier integrated pharmacy...
CVS Corporation (NYSE:CVS) and Caremark Rx, Inc. (NYSE:CMX) today issued the following update regarding the closing date for the CVS/Caremark merger: ?We have been advised...
NEW YORK, March 16 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P 100, S&P 500, and S&P MidCap 400 indices after the close of trading on Tuesday, March 20:...
Innovation and Execution Delivers Value for Stockholders, Plan Sponsors and Patients ST. LOUIS, March 16 /PRNewswire-FirstCall/ -- Express Scripts, Inc. (NASDAQ:ESRX) today issued the following...
In response to the results of today?s Caremark Rx, Inc. (NYSE: CMX) shareholder vote approving the CVS/Caremark merger, CVS Corporation (NYSE: CVS) issued the following...
Advisory Services, Analysts, Stockholders Support Express Scripts Position Company Urges Caremark Stockholders to Vote GOLD Proxy Card AGAINST The Flawed Caremark Merger Process ST. LOUIS, March...
CVS Corporation (NYSE: CVS) said its shareholders have voted to approve the company?s merger with Caremark Rx, Inc. (NYSE: CMX) at the special shareholder meeting held earlier...
Urges Caremark Stockholders to Vote GOLD Proxy Card AGAINST The Flawed Caremark Merger Process ST. LOUIS, March 14 /PRNewswire-FirstCall/ -- Express Scripts, Inc. (NASDAQ:ESRX) today issued an...
ST. LOUIS, March 14 /PRNewswire-FirstCall/ -- Express Scripts, Inc. (NASDAQ:ESRX) today announced that Glass, Lewis & Co. ("Glass Lewis"), a leading independent voting advisory service...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
